ABSTRACT
Antecedentes: la rinitis alérgica afecta a 20 millones de personas en Estados Unidos y a un número muy superior en el resto del mundo. Objetivo: evaluar la eficacia y la seguridad de la fexofenadina en comparación con la cetirizina en el tratamiento de la rinitis alérgica. Material y método: se realizó un estudio prospectivo, doble ciego, comparativo, al azar y multicéntrico en pacientes con rinitis alérgica con edades comprendidas entre los 12 y 65 años. En la primera fase se administró placebo durante tres días a todos los pacientes y posteriormente se asignaron por azar para recibir fexofenadina a la dosis de 120 mg o 10 mg de cetirizina en dosis única al día durante 14 días. Al inicio y al final del estu dio se realizaron pruebas de laboratorio y gabinete que sirvieron como parámetros para conocer la inocuidad, eficacia y evaluación global por parte del investigador. Resultados: se incluyeron 176 pacientes, 63.6 por ciento de ellos eran mujeres. La edad promedio fue 27.8 años (ñ 12.0). El 47.7 por ciento de la muestra recibió fexofenadina y 52.2 por ciento cetirizina. No se encontró una diferencia significativa ni en parámetros de eficacia ni en la inocuidad. Conclusión: los resultados de este estudio permiten corroborar la eficacia e inocuidad de la fexofenadina.
Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Cetirizine , Histamine H1 Antagonists , Rhinitis, Allergic, Perennial/drug therapy , Efficacy , Treatment OutcomeABSTRACT
The influence of ACD and CPDA-1 anticoagulants, and storage time for 3 and 6 months on F VIII:C activity were compared in cryprecipitate obtained at -70ºC, and -30ºC plasma freezing temperature. To eliminate variations in F VIII:C activity between donor plasma, the cryoprecipitation at -70ºC and -30ºC was made in paired plasma volumes (approximately 100 ml) from each blood unit. Employing ACD plasmas (n= 50), there was no significant difference in F VIII:C activity between cryoprecipitate prepared at -70ºC (X=31.1 IU/bag) and -30ºC was made in paired plasma volumes (approximately 100 ml) from each blood unit. Employing ACD plasmas (n= 50), there was no significant difference in F VIII:C activity between cryprecipitate prepared at -70ºC (X= 31.1 IU/bag) and -30ºC (X = 30.5 IU/bag), and the storage did not modifify FVIII:C activity. In contrast, in cryprecipitate prepared from CPDA-1 plasma (n= 31), the F VIII:C levels obtained at-30ºC (X= 43.8IU/bag) were significantly higher than those at-70ºC (X=37.3 IU/bag), but a deterioration of F VIII:C activity (about 50 percent) was observed after 6 months of cryprecipitate storage. Therefore, if cryprecipitate is stored it stored it would be more convenient to use ACD instead of CPDA-1 and make cryoprecipitation either at-70ºC or-30ºC
Subject(s)
Anticoagulants/metabolism , Cryopreservation/standards , Factor VIII/pharmacokinetics , Freezing , Plasma/physiologyABSTRACT
Pregnancy and infancy are the most critical physiological stages for iron nutrition. During the third trimester of pregnancy the daily iron requirement is from 0.7 to 0.8 mg; during the first year of life the daily requirement is from 0.9 to 1 mg. Since no natural unsupplemented diet could be expected to provide iron in such large amounts, it would seem that these requirements should be met from individuals iron stores or from supplementation. As a rule, however, adequate iron stores are uncommon in females of reproductive age, and, consequently, the prevalence of iron deficiency anemia in pregnant women is generally high, though its frequency varies from region to region, and even within a region, where it bears a relationship to the socioeconomic status and the eating habits of the population. Thus, definite anemia (hemoglobin below 10 mg/100 ml) has been observed in 40 to 50 per cent of the pregnant women in certain population of India and Trinidad, but in only 0 and 2 per cent of Australian and Bantu women. In studies of several groups of pregnant women living in poor socioeconomic conditions, anemia (hemoglobin below 12 mg) has been found in 19 to 36 per cent and iron deficiency (saturation index below 15 per cent) in 21 to 64.5 per cent
Information is lacking on the subject of iron stores and the ...(AU)
Subject(s)
16595/analysis , Iron/metabolism , Primary Health Care , Nutrition Disorders/economics , Nutrition Disorders/education , India , Trinidad and Tobago , AustraliaABSTRACT
Pregnancy and infancy are the most critical physiological stages for iron nutrition. During the third trimester of pregnancy the daily iron requirement is from 0.7 to 0.8 mg; during the first year of life the daily requirement is from 0.9 to 1 mg. Since no natural unsupplemented diet could be expected to provide iron in such large amounts, it would seem that these requirements should be met from individuals iron stores or from supplementation. As a rule, however, adequate iron stores are uncommon in females of reproductive age, and, consequently, the prevalence of iron deficiency anemia in pregnant women is generally high, though its frequency varies from region to region, and even within a region, where it bears a relationship to the socioeconomic status and the eating habits of the population. Thus, definite anemia (hemoglobin below 10 mg/100 ml) has been observed in 40 to 50 per cent of the pregnant women in certain population of India and Trinidad, but in only 0 and 2 per cent of Australian and Bantu women. In studies of several groups of pregnant women living in poor socioeconomic conditions, anemia (hemoglobin below 12 mg) has been found in 19 to 36 per cent and iron deficiency (saturation index below 15 per cent) in 21 to 64.5 per cent
Information is lacking on the subject of iron stores and the ...(AU)
Publicado en inglés en Publicación Científica de la OPS 184(65-71)
